Analysts Set Bausch Health Companies Inc. (NYSE:BHC) Price Target at $7.33

Bausch Health Companies Inc. (NYSE:BHC) has received a consensus recommendation of “Hold” from the six research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $7.33.

Several research analysts have recently weighed in on the stock. StockNews.com cut shares of Bausch Health Companies from a “buy” rating to a “hold” rating in a research note on Tuesday. Royal Bank of Canada lowered their target price on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research report on Friday, August 2nd. Piper Sandler cut Bausch Health Companies from a “neutral” rating to an “underweight” rating and reduced their price target for the stock from $9.00 to $3.00 in a research report on Friday, August 2nd. Scotiabank lowered their price objective on Bausch Health Companies from $10.00 to $8.50 and set a “sector perform” rating on the stock in a research report on Friday, August 2nd. Finally, Raymond James initiated coverage on Bausch Health Companies in a research note on Wednesday, July 10th. They set a “market perform” rating and a $8.00 price objective for the company.

Insider Activity at Bausch Health Companies

In other Bausch Health Companies news, EVP Seana Carson sold 13,370 shares of the company’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $6.21, for a total value of $83,027.70. Following the completion of the transaction, the executive vice president now directly owns 435,198 shares in the company, valued at approximately $2,702,579.58. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 8.12% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BHC. Principal Securities Inc. bought a new stake in shares of Bausch Health Companies in the fourth quarter worth about $31,000. Salem Investment Counselors Inc. bought a new stake in Bausch Health Companies in the 1st quarter worth approximately $32,000. Headlands Technologies LLC purchased a new stake in shares of Bausch Health Companies during the 2nd quarter worth approximately $35,000. MQS Management LLC bought a new position in shares of Bausch Health Companies during the 2nd quarter valued at approximately $71,000. Finally, Certuity LLC purchased a new stake in Bausch Health Companies during the second quarter valued at $75,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Stock Performance

Bausch Health Companies stock opened at $8.19 on Friday. Bausch Health Companies has a one year low of $3.96 and a one year high of $11.46. The stock has a fifty day moving average of $6.25 and a 200 day moving average of $7.35. The stock has a market cap of $2.96 billion, a PE ratio of -6.60 and a beta of 0.75.

Bausch Health Companies (NYSE:BHC) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. The firm had revenue of $2.40 billion during the quarter, compared to analyst estimates of $2.33 billion. Bausch Health Companies had a negative net margin of 5.12% and a negative return on equity of 742.06%. During the same quarter in the prior year, the firm earned $0.81 EPS. As a group, sell-side analysts predict that Bausch Health Companies will post 3.61 EPS for the current fiscal year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.